Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma
10.1007/s13139-019-00608-8
- Author:
Jolanta KRAJEWSKA
1
;
Michal JARZAB
;
Aleksandra KUKULSKA
;
Agnieszka CZARNIECKA
;
Jozef ROSKOSZ
;
Zbigniew PUCH
;
Zbigniew WYGODA
;
Ewa PALICZKA-CIESLIK
;
Aleksandra KROPINSKA
;
Aleksandra KROL
;
Daria HANDKIEWICZ-JUNAK
;
Barbara JARZAB
Author Information
1. Nuclear Medicine and Endocrine Oncology Department, M.Sklodowska-Curie Institute-Oncology Center, Gliwice Branch, Wybrzeze AK 15, 44-101 Gliwice, Poland. jolanta.krajewska@io.gliwice.pl
- Publication Type:Original Article
- Keywords:
Differentiated thyroid cancer;
Radioiodine treatment;
Low-risk differentiated thyroid cancer;
Recurrence;
Relapse
- MeSH:
Diagnosis;
Follow-Up Studies;
Humans;
Recurrence;
Retrospective Studies;
Thyroglobulin;
Thyroid Gland;
Thyroid Neoplasms;
Thyroidectomy
- From:Nuclear Medicine and Molecular Imaging
2019;53(5):320-327
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Although postoperative radioiodine (RAI) therapy has been used in patients with differentiated thyroid carcinoma (DTC) for many years, there is still lack of data defining the timing of RAI administration. A retrospective analysis was carried out to answer the question whether the time of postoperative RAI treatment demonstrated any impact on long-term outcomes, particularly in low-risk DTC.MATERIAL: The analyzed group involved 701 DTC patients staged pT(1b)-T₄N₀-N₁M₀, who underwent total thyroidectomy and postoperative RAI therapy. According to the time interval between DTC diagnosis and RAI administration, patients were allocated to one of three groups: up to 9 months (N = 150), between 9 and 24 months (N = 323), and > 24 months (N = 228). Median follow-up was 12.1 years (1.5−15.2).RESULTS: Based on an initial DTC advancement and postoperative stimulated thyroglobulin concentration patients were stratified as a low-, intermediate-, and high-risk group. Low-risk patients, who received RAI therapy up to 9 months, demonstrated significantly lower risk of relapse comparing to those, in whom RAI was administered between 9 and 24 months and after 24 months since DTC diagnosis: 0%, 5.5%, and 7.1%, respectively. Regarding intermediate- and high-risk groups, the differences in the timing of postoperative RAI treatment were not significant.CONCLUSION: If postoperative RAI treatment is considered in low-risk DTC, any delay in RAI administration above 9 months since diagnosis may be related to poorer long-term outcomes.
